Dr. Victor M. Tang is a scientist at the Institute for Mental Health Policy Research and an addictions psychiatrist within the Addictions Division at the Centre for Addiction and Mental Health (CAMH). He is also an assistant professor in the Department of Psychiatry at the University of Toronto. He completed a Bachelor of Science in Psychology and Master of Science in Neuroscience at the University of British Columbia, his medical training at Queen's University, and his psychiatry residency in the Clinician Scientist Program at the University of Toronto. He recently completed a clinical research fellowship with joint training between the Addictions Division and Temerty Centre for Therapeutic Brain Intervention at CAMH, and was an NIDA-funded Research in Addiction Medicine Scholar through Yale University and Boston University. The goal of Dr. Victor M. Tang’s research program is to develop novel therapeutics and improve treatment outcomes for patients with mood disorders and substance use disorders.
Daniel M. Blumberger is the scientific director of the Temerty Centre for Therapeutic Brain Intervention, co-chief of General Adult Psychiatry and Health Systems, and a senior scientist at the Centre for Addiction and Mental Health (CAMH). He additionally holds the Temerty Chair in Therapeutic Brain Intervention at CAMH. He is a subspecialist in geriatric psychiatry, a Professor at the Department of Psychiatry in the Temerty Faculty of Medicine at the University of Toronto, and a full member of the Institute of Medical Sciences. He received his MD and completed residency training in psychiatry at the University of Toronto. After completing his residency training, he completed his MSc in neuroscience through the Institute of Medical Sciences, and completed a fellowship in brain stimulation and geriatric psychiatry funded by the Canadian Institute of Health Research, and received a NARSAD young investigator award from the Brain and Behavior Research Foundation. His research focuses on the use of interventional psychiatry approaches with a focus on brain stimulation therapies for refractory psychiatric disorders. His main research focuses on clinical intervention trials of novel treatments and understanding the neurobiology of treatment-resistant depression across a patient's lifespan.
Dr. Tony P. George is a senior scientist at CAMH’s Institute for Mental Health Policy Research (IMHPR), and a professor of psychiatry at the Institute of Medical Sciences (IMS) at the Temerty Faculty of Medicine, University of Toronto (UofT). He was on the Yale Psychiatry faculty from 1998 to 2007, and then moved to Toronto as the inaugural Chair of Addiction Psychiatry at UofT (2006–2012). He has served in several senior clinical and administrative positions at CAMH and the Department of Psychiatry at UofT since 2008. Dr. Tony P. George has published over 325 peer-reviewed original research articles, reviews, and other reports. Since 2023, he has been co-principal editor of the journal of the American College of Neuropsychopharmacology (ACNP), Neuropsychopharmacology. He also wrote the chapter on Nicotine and Tobacco for the Cecil Textbook of Medicine in 2011, 2015, 2019, and the new 2023 editions. In 2022, he was appointed Chair of the Scientific Advisory Committee of the Canadian Centre for Substance Use and Addiction (CCSA). Dr. Tony P. George’s BACDRL Lab at CAMH focuses on understanding the biology of addiction co-morbidity in people with serious mental illness (e.g. schizophrenia, mood disorders, PTSD), and translating this knowledge towards novel and more effective treatment for concurrent disorders. His research program (BACDRL) is supported by recent project grants from CIHR and NIDA/NIH.
Dr. Joshua L. Gowin currently works at the University of Colorado Anschutz Medical Campus in the Department of Radiology. He uses functional MRI and psychopharmacology to investigate mental health conditions. Before that, he trained at the National Institute on Alcohol Abuse and Alcoholism and at the University of California San Diego. He earned his doctorate in behavioral neuroscience from the University of Texas Health Science Center at Houston in 2011 for his work on the cycle of violence and the processes in the brain that may underlie it.
Dr. Bernard Le Foll is a senior scientist specializing in addiction within the Institute for Mental Health Policy Research at CAMH. Additionally, Dr. Bernard Le Foll is chair of addiction psychiatry within the Department of Psychiatry of University of Toronto and a professor in the departments of Family and Community Medicine, Pharmacology and Toxicology, Psychiatry, Institute of Medical Sciences and the Dalla Lana School of Public Health. Dr. Bernard Le Foll received specialized training in drug addiction and behavioral and cognitive therapy at Paris University in France. He has written treatment guidelines and has been the coordinator of clinical trials. He obtained a PhD in pharmacology at INSERM and completed a Post-doctoral Fellowship at the National Institutes of Health. He has received scientific prizes and awards from the Canadian Institutes for Health Research, the National Institutes of Health, the French Academy of Medicine, the American College for Neuropsychopharmacology, the College on Problems on Drug Dependence, the Society for Research on Nicotine and Tobacco, the Brain and Behavior Foundation, Pfizer, OPGRC, the Ontario Lung Association, and the Heart and Stroke Foundation. The goal of his research is to improve treatment of drug addiction. For this purpose, various approaches are used such as clinical trials, laboratory experiments, and multi-disciplinary basic research approaches. The goal is to develop novel therapeutic strategies in clinical populations.
Matthew E. Sloan is an Assistant Professor at the Department of Psychology, University of Toronto, Scarborough. He is a clinician scientist specializing in the treatment of substance use disorders and their psychiatric comorbidities. He completed medical school and psychiatry residency at McGill University, followed by a postdoctoral fellowship in Human Psychopharmacology at the National Institutes of Health and an Addiction Psychiatry fellowship at Yale University. His primary research interests are developing innovative new treatments for substance use disorders and exploring determinants of psychopharmacological response to drugs of abuse. He has received scientific prizes from the American Academy of Addiction Psychiatry and the National Institute on Alcohol Abuse and Alcoholism. His main areas of research include Psychopharmacology, Addiction, and the Endocannabinoid System.
